Adverse drug reactions in the post coronary care unit inpatients of a teaching hospital

Iranian Journal of Pharmaceutical Research

Volumn 7, Issue 3, 2008, Pages 223-228

  Fahimi, Fanak ^a   Baniasadi, Shadi ^a   Amini, Somayeh ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Adverse drug reaction reporting system; Cardiovascular drugs; Coronary care unit; Hospital

Indexed keywords

AMLODIPINE; ANTICOAGULANT AGENT; ATENOLOL; CAPTOPRIL; CARDIOVASCULAR AGENT; DIGOXIN; DILTIAZEM; ENALAPRIL; ENOXAPARIN; FUROSEMIDE; GLYCERYL TRINITRATE; HEPARIN; HYDROCHLOROTHIAZIDE; ISOSORBIDE; LOSARTAN; METOPROLOL; PROPRANOLOL; SPIRONOLACTONE; WARFARIN;

ADULT; ARTICLE; BLEEDING DISORDER; BLOOD CLOTTING DISORDER; BRONCHOSPASM; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CONGESTIVE HEART FAILURE; CORONARY CARE UNIT; DEMOGRAPHY; DRUG INDUCED DISEASE; DRUG MONITORING; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HEALTH CARE QUALITY; HEART ARRHYTHMIA; HOSPITAL PATIENT; HUMAN; HYPERTENSION; INCIDENCE; INFORMATION DISSEMINATION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; METABOLIC DISORDER; MUSCULOSKELETAL DISEASE; NUTRITIONAL DISORDER; OUTCOME ASSESSMENT; PATIENT CARE; PERIPHERAL NEUROPATHY; RESPIRATORY TRACT DISEASE; SKIN APPENDAGE DISEASE; SKIN DISEASE; TEACHING HOSPITAL; TERTIARY HEALTH CARE; THROMBOCYTE DISORDER; UNSPECIFIED SIDE EFFECT; URINARY DYSFUNCTION; VASCULAR DISEASE;

EID: 68949213937     PISSN: 17350328     EISSN: 17266890     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. World Health Organization. Technical Report Series 498. World Health Organization, Geneva (1972)
2. Murphy BM and Frigo LC. Development, implementation, and results of a successful multidisciplinary adverse drug reaction reporting program in a university teaching hospital. Hosp. Pharm. (1993) 28: 1199-1204, 1240
3. Ramesh M, Pandit J and Parthasarathi G. Adverse drug reactions in a South Indian hospital-their severity and cost involved. Pharmacoepidemiol Drug Saf. (2003) 12: 687-92
4. Bates DW, Cullen DJ, Laird N, Petersen LA, Small SD, Servi D, Laffel G, Sweitzer BJ, Shea BF, Hallisey R,Vander Vliet M, Nemeskal R and Leape LL. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. JAMA (1995) 274: 29-34
5. Classen C, Pestotnik SL, Evans RS and Burke JP. Computerized surveillance of adverse drug events in hospital patients. JAMA (1991) 266: 2847-51
6. Tran C, Knowles SR, Liu BA and Shear NH. Gender differences in adverse drug reactions. J.Clin. Pharmacol. (1998) 38: 1003-9
7. McDowell SE, Coleman JJ and Ferner RE. Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine. BMJ (2006) 332: 1177-81
8. Thurmann PA. Methods and systems to detect adverse drug reactions in hospitals. Drug Saf. (2001) 24: 961-8
9. Baniasadi S, Fahimi F and Shalviri G. Developing an adverse drug reaction reporting system at a teaching hospital. Basic Clin. Pharmacol. Toxicol.(2008) 102: 408-11
10. Uppsala Monitoring Centre. Adverse Reaction Terminology. Uppsala, World Health Organization Collaborating Centre for International Drug Monitoring (2003)
11. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C and Greenblatt DJ. A method for estimating the probability of adverse drug reactions. Clin. Pharmacol. Ther. (1981) 30: 239-45
12. Schumock GT and Thornton JP. Focusing on the preventability of adverse drug reactions. Hosp. Pharm. (1992) 27: 538
13. Classen C, Pestotnik SL, Evans RS, Lloyd JF and Burke JP. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA (1997) 277: 301-6
14. Zaidenstein R, Eyal S, Efrati S, Akivison L, Michowitz MK, Nagornov V and Golik A. Adverse drug events in hospitalized patients treated with cardiovascular drugs and anticoagulants. Pharmacoepidemiol. Drug Saf. (2002) 11: 235-8
15. Hoigne R, Lawson DH and Weber E. Risk factors for adverse drug reactions- epidemiological approaches. Eur. J. Clin. Pharmacol. (1990) 39: 321-5
16. Gurwitz JH and Avorn J. The ambiguous relation between aging and adverse drug reactions. Ann. Intern. Med. (1991) 114: 956-66
17. Carbonin P, Pahor M, Bernabei R and Sgadari A. Is age an independent risk factor of adverse drug reactions in hospitalised medical patients? J. Am. Geriatric Soc. (1991) 39: 1093-9
18. Moore N, Lecointre D, Nobelt C, Mabille M. Frequency and cost of serious adverse drug reactions in a department of general medicine. Br. J. Clin Pharmacol. 1998; 45:301-8
19. Leape LL, Brennan TA, Laird N, Lawthers AG, Localio AR, Barnes BA, Hebert L, Newhouse JP, Weiler PC and Hiatt H. The nature of adverse events in hospitalized patients-Results of Harvard medical practice study II. N. Engl. J. Med. (1991) 324: 377-84
20. Al-Tajir GK and Kelly WN. Epidemiology, comparative methods of detection, and preventability of adverse drug events. Ann. Pharmacother. (2005) 39: 1169-74